Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atorvastatin calcium, quantity: 20.68 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 4000; pregelatinised maize starch; activated attapulgite; magnesium stearate; hypromellose; titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; hyprolose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 82.72 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hyprolose; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; macrogol 4000; activated attapulgite; titanium dioxide; hypromellose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 41.36 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: activated attapulgite; microcrystalline cellulose; lactose monohydrate; titanium dioxide; magnesium stearate; hypromellose; macrogol 4000; colloidal anhydrous silica; pregelatinised maize starch; hyprolose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 20.68 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; macrogol 4000; colloidal anhydrous silica; microcrystalline cellulose; activated attapulgite; titanium dioxide; pregelatinised maize starch; hyprolose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 10.34 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; pregelatinised maize starch; macrogol 4000; magnesium stearate; lactose monohydrate; titanium dioxide; hyprolose; microcrystalline cellulose; activated attapulgite; hypromellose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 82.72 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; macrogol 4000; hypromellose; hyprolose; activated attapulgite; microcrystalline cellulose; magnesium stearate; titanium dioxide; lactose monohydrate - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 41.36 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: macrogol 4000; pregelatinised maize starch; lactose monohydrate; hyprolose; magnesium stearate; titanium dioxide; activated attapulgite; hypromellose; colloidal anhydrous silica; microcrystalline cellulose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 20.68 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: titanium dioxide; activated attapulgite; colloidal anhydrous silica; macrogol 4000; hypromellose; hyprolose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - atorvastatin calcium, quantity: 10.34 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; activated attapulgite; colloidal anhydrous silica; hypromellose; hyprolose; magnesium stearate; macrogol 4000; pregelatinised maize starch; titanium dioxide - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

United States - English - NLM (National Library of Medicine)

sandoz inc - atorvastatin calcium trihydrate (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 10 mg - atorvastatin calcium tablets are indicated: risk summary discontinue atorvastatin calcium when pregnancy is recognized. alternatively, consider the ongoing therapeutic needs of the individual patient. atorvastatin calcium decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, atorvastatin calcium may cause fetal harm when administered to pregnant patients based on the mechanism of action [see clinical pharmacology ( 12.1)]. in addition, treatment of hyperlipidemia is not generally necessary during pregnancy. atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. published